Assignee
BOLD THERAPEUTICS INC
CA·6 granted patents·6 pending applications·14 citations·filing 2017–2025
Top patents by PatentIndex Score
12 records- 0195US11040993B2Manufacture of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereofBOLD THERAPEUTICS INC·Filed 2020·Granted Jun 22, 2021·4 cites·31 claims
- 0293US11739111B2Manufacture of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereofBOLD THERAPEUTICS INC·Filed 2021·Granted Aug 29, 2023·2 cites·8 claims
- 0393US10611787B2Manufacture of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereofBOLD THERAPEUTICS INC·Filed 2018·Granted Apr 7, 2020·4 cites·7 claims
- 0486US12415825B2Manufacture of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereofBOLD THERAPEUTICS INC·Filed 2023·Granted Sep 16, 2025·0 cites·9 claims
- 0585US2026042792A1Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereofBOLD THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0682US10821095B2Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancerBOLD THERAPEUTICS INC·Filed 2017·Granted Nov 3, 2020·4 cites·9 claims
- 0770US2024091196A1Use of trans-[tetrachlorobis(1h-indazole)ruthenate(iii)] for the treatment of cancerBOLD THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0865US2025387370A1Use of trans-[tetrachlorobis(1h-indazole)ruthenate(iii)] for the treatment of cancerBOLD THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0963US11633380B2Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancerBOLD THERAPEUTICS INC·Filed 2020·Granted Apr 25, 2023·0 cites·10 claims
- 1050US2024115582A1Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancersBOLD THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1146US2025235465A1Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] to ameliorate proteasome inhibitor resistanceBOLD THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1245US2023024119A1Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancersBOLD THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →